Venclexta

Free

Venclexta is a BCL-2 inhibitor which contains Venetoclax. Venclexta uses are:

For treating chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), with or without 17p deletion, patients have received at least one therapy beforehand.

In combination with medication, azacitidine or decitabine, or low-dose cytarabine to treat newly-diagnosed acute myeloid leukemia (AML) in adult patients aged 75 years or older or with comorbidities that preclude the use of intensive induction chemotherapy.

Submit an Enquiry

Note: Venclexta is an FDA approved drug

Category: Innovator Products Brand: Abbvie

Description
Reviews (0)

Description

Patients taking treatment with venclexta 100 mg tablets should be monitored for blood chemistries and manage abnormalities promptly. Patients with venetoclax 100 mg / 50 mg /10 mg should be monitored for complete blood counts throughout the treatment period.

Avoid administering live attenuated vaccines before, during, or after treatment with venetoclax 50 mg /10 mg /100 mg until B-cell recovery occurs. Mechanism of action and findings suggest that venclexta uses may cause embryo-fetal harm if administered to a pregnant woman.

Respective nursing women should not breastfeed their child while taking venetoclax 10 mg / 50 mg /100 mg.